CMS identifies Medicare billing codes for combination antibody therapy
The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System codes for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.
The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.
Related News Articles
Headline
A new report from KFF reveals that Medicare Advantage enrollees had access to just 48% of the physicians available to Traditional Medicare beneficiaries in…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…
Headline
The Centers for Medicare & Medicaid Services has released an operational guide for Medicare-enrolled providers and suppliers on the Wasteful and…
Headline
A report by the Department of Health and Human Services Office of the Inspector General found that many Medicare Advantage and Medicaid managed care plans…
Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…